Donafenib and GSK‐J4 Synergistically Induce Ferroptosis in Liver Cancer by Upregulating HMOX1 Expression

Donafenib and GSK‐J4 Synergistically Induce Ferroptosis in Liver Cancer by Upregulating HMOX1 Expression

Abstract Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide. Donafenib is a multi‐receptor tyrosine kinase inhibitor approved for the treatment of patients with advanced HCC, but its clinical effect is very limited. Here, through integrated screening of a small‐molecule inhib...

Full description

Bibliographic Details
Main Authors: Chenyang Zheng, Bo Zhang, Yunyun Li, Kejia Liu, Wei Wei, Shuhang Liang, Hongrui Guo, Kun Ma, Yao Liu, Jiabei Wang, Lianxin Liu
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:Advanced Science
Subjects:
donafenib
ferroptosis
gsk‐j4
hmox1
synthetic lethal
Online Access:https://doi.org/10.1002/advs.202206798

Similar Items

Similar Items